Disability

Zynerba Pharmaceuticals Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol Therapy in Fragile X Syndrome

Staff January 11, 2023

Comprehensive data review suggests a central role for the endocannabinoid system (ECS) in neuronal development, cognitive function and in the...

Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises

Staff January 8, 2023

Mid-stage and Pivotal Trials of ANX005, ANX007 and ANX1502 Poised to Achieve Numerous Catalysts in Multiple Disease Indications Well-Capitalized with...

Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures

Staff January 5, 2023

LAVAL, Québec, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST),...

“Modern Miracles”: ReWalk Technology Showcased at the Hanukkah Celebration Hosted by the Embassy of the State of Israel to Belgium and Luxembourg in Antwerp

Staff January 5, 2023

ReWalk Robotics, Ltd. is honored to have presented its technology at the prestigious Modern Miracles Celebration with the Embassy of...

Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) – Updated Interim Results for the Six Months Ended 30 June 2022

Staff December 30, 2022

LONDON, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (“Tiziana”, NASDAQ: TLSA), a biotechnology company enabling breakthrough CNS...

Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia

Staff December 28, 2022

LAVAL, Québec, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST),...

Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) – Interim Results for the Six Months Ended 30 June 2022

Staff December 28, 2022

Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet needLONDON, Dec. 27, 2022...

atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL-007 for Cognitive Impairment Associated with Schizophrenia

Staff December 19, 2022

The phase 2b proof-of-concept trial will evaluate the novel compound, RL-007, for pro-cognitive effects in patients with Cognitive Impairment Associated...

PepGen Announces IND-Enabling Preclinical Data Supporting Progression of PGN-EDODM1 into Clinical Studies

Staff December 7, 2022

DMPK Transcript Levels Figure 1. No significant changes in mean DMPK transcript levels were observed in DM1 patient cells or...

Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting

Staff December 7, 2022

Improvement in cognitive and physical functioning, measured by the CPFQ patient-rated scale, starting at week 1 and sustained over 12...

AmMax Bio Announces Oral Presentation of Phase 2 Data of AMB-05X for the Treatment of Tenosynovial Giant Cell Tumor (TGCT) at the 2022 CTOS Annual Meeting

Staff November 18, 2022

Using local administration for a local disease, positive clinical results suggest AMB-05X could become best-in-class treatment for the diverse population...

SPR Therapeutics Debuts Occipital Nerve Stimulation Data at ASRA 2022

Staff November 17, 2022

One of six total abstracts accepted highlighting benefits of the SPRINT® PNS SystemCLEVELAND, Nov. 17, 2022 (GLOBE NEWSWIRE) -- At...

OneStep Launches Industry-First Upper Body Range of Motion Capabilities

Staff November 17, 2022

With Only a Smartphone, Providers Can Gain Insight Into Fine Motion Details to Provide Better CareNEW YORK, Nov. 17, 2022...

Route 92 Medical Announces Expansion to New Manufacturing Site in Salt Lake City, Utah

Staff November 16, 2022

SAN MATEO, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated...

MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update

Staff November 14, 2022

MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update Global trial of sonelokimab in Hidradenitis Suppurativa...

Osteal Therapeutics, Inc. Completes Enrollment in APEX Phase 2 Clinical Trial of VT-X7 for Periprosthetic Joint Infection

Staff November 4, 2022

Six-month outcomes are expected in second quarter of 2023DALLAS, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Osteal Therapeutics, Inc. (“Osteal”), a...

Cingulate Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead Candidate for Treatment of ADHD

Staff November 1, 2022

Study Conducted by Dr. Vince Clinical ResearchKANSAS CITY, Kan., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a...

Dick and Betsy DeVos Family Foundation, SoldierStrong Donate Robotic Exoskeleton, Virtual Reality Treatment System to Help Vets Take Next Step Forward

Staff October 29, 2022

ORLANDO, Fla., Oct. 28, 2022 (GLOBE NEWSWIRE) -- The Dick and Betsy DeVos Family Foundation and SoldierStrong today announced donations...

TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis

Staff October 26, 2022

NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting exploratory analyses from...

Study Finds Majority of Kentuckians Favor Universal Healthcare

Staff October 24, 2022

LOUISVILLE, Ky., Oct. 24, 2022 (GLOBE NEWSWIRE) -- An overwhelming majority of Kentuckians favor a national government health plan, according...